Related Experiment Video
Updated: Mar 17, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Pyruvate dehydrogenase kinase regulates hepatitis C virus replication
Gwon-Soo Jung1,2, Jae-Han Jeon1,2, Yeon-Kyung Choi1,2
1Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Republic of Korea.
Hepatitis C virus (HCV) infection alters host cell metabolism, increasing glycolysis and nucleotide synthesis. Inhibiting pyruvate dehydrogenase kinase (PDK) suppressed viral replication, suggesting PDK as a therapeutic target.
Area of Science:
- Virology
- Cellular Metabolism
- Biochemistry
Background:
- Hepatitis C virus (HCV) replication depends on host cell macromolecules.
- HCV infection necessitates host cellular metabolic reprogramming towards aerobic glycolysis.
Purpose of the Study:
- To investigate the role of pyruvate dehydrogenase kinase (PDK) in regulating HCV replication.
- To determine if targeting PDK can inhibit HCV.
Main Methods:
- Compared protein and mRNA expression of metabolic regulators (c-Myc, HIF-1α, PDKs, glycolytic enzymes) in HCV-infected vs. uninfected cells.
- Utilized c-Myc inhibitor (JQ1) and PDK inhibitor (dichloroacetate, DCA).
- Assessed viral replication and enzyme expression following inhibitor treatment, alone and with IFN-α or ribavirin.
Main Results:
- HCV infection significantly upregulated c-Myc, HIF-1α, glycolytic, and serine biosynthetic enzymes.
- JQ1 and DCA decreased these enzymes in infected cells, suppressing viral replication.
- DCA enhanced the antiviral effects of IFN-α and ribavirin.
Conclusions:
- HCV reprograms host metabolism to favor glycolysis and serine biosynthesis, partly via increased PDK activity.
- Increased PDK activity supplies nucleotide precursors essential for viral replication.
- Blocking PDK activity shows therapeutic potential against HCV.
Related Concept Videos
Viruses with RNA Genomes
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
Inhibition of Cdk Activity
Hepatic Drug Excretion: Influencing Factors

